

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 27, 2020

---

AIMMUNE THERAPEUTICS, INC.  
(Exact name of registrant as specified in its charter)

---

Delaware  
(State or other jurisdiction  
of incorporation)

001-37519  
(Commission  
File Number)

45-2748244  
(IRS Employer  
Identification Number)

8000 Marina Blvd, Suite 300  
Brisbane, CA 94005  
(Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: (650) 614-5220

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of each exchange on which registered</u>
Common Stock, par value \$0.0001 per share	AIMT	NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On May 27, 2020, Aimmune Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on three proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 9, 2020. Only stockholders of record as of the close of business on March 31, 2020, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, 65,222,917 shares of the Company’s common stock were outstanding and entitled to vote at the Annual Meeting. The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as follows:

*Proposal 1.* The election of three directors to hold office until the 2023 annual meeting of stockholders or until their respective successor is elected:

<b>Nominee</b>	<b>Votes For</b>	<b>Votes Withheld</b>	<b>Broker Non-Votes</b>
Mark McDade	34,480,200	10,675,109	10,070,278
Dr. Brett Haumann	36,938,323	8,216,986	10,070,278
Stacey Seltzer	36,922,814	8,232,495	10,070,278

*Proposal 2.* The ratification of the selection, by the audit committee of the board of directors of the Company, of KPMG, LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2020:

<b>Votes For</b>	<b>Votes Against</b>	<b>Abstentions</b>
55,074,795	99,299	51,493

As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.

*Proposal 3.* The approval, on a non-binding, advisory basis, of the compensation of the Company’s named executive officers:

<b>Votes For</b>	<b>Votes Against</b>	<b>Abstentions</b>	<b>Broker Non-Votes</b>
44,271,521	798,783	85,005	10,070,278

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AIMMUNE THERAPEUTICS, INC.**

Date: May 28, 2020

By: /s/ Douglas T. Sheehy  
Douglas T. Sheehy  
General Counsel and Secretary